stockrowIndivior Pharmaceuticals Inc.
SUPN Healthcare Drug Manufacturers Specialty & Generic
Indivior Pharmaceuticals Inc.’s revenue for fiscal 2025 (year ended December 2025) was $1.2 billion, up 4.29% from fiscal 2024.
- Revenue
- +13.4%
- EPS
- +241.5%
- Free cash flow
- +240.7%
- Total debt
- +51.6%
Quarter to September 2026, against a year earlier
Follow SUPN
Alert me
Indivior Pharmaceuticals Inc. (SUPN) Net income
Indivior Pharmaceuticals Inc.'s net income for fiscal 2025 was $210.0M, up 2,900.0% from $7.0M in fiscal 2024. Over the twelve months to 30 September 2026 it was $450.0M. Over the past ten years it has ranged from −$156.0M (fiscal 2020) to $346.0M (fiscal 2015); the current reading is higher than 73% of that period. Indivior Pharmaceuticals Inc. ranks 8th of 84 Drug Manufacturers Specialty & Generic companies by net income.
Net income, annual
Embed this chart
Annual newest first
| Period | Net income | Change |
|---|---|---|
| FY2025 | $210.0M | 2,900.00% |
| FY2024 | $7.0M | — |
| FY2023 | −$129.0M | — |
| FY2022 | −$85.0M | — |
| FY2021 | $213.0M | — |
| FY2020 | −$156.0M | — |
| FY2019 | $178.0M | (39.04%) |
| FY2018 | $292.0M | 51.30% |
| FY2017 | $193.0M | 29.53% |
| FY2016 | $149.0M | (56.94%) |
Quarterly newest first
| Period | Net income | Change |
|---|---|---|
| Sep 2026 | $137.0M | 12.30% |
| Jun 2026 | $122.0M | 37.08% |
| Mar 2026 | $89.0M | (12.75%) |
| Dec 2025 | $102.0M | 137.21% |
| 43 more quarters | Free account |
Against its own ten years
Net income against peers
| Company | Net income |
|---|---|
| SUPN Indivior Pharmaceuticals Inc. | $450.0M |
| RDY Dr. Reddy's Laboratories Ltd compare | $273.0M |
| LNTH Lantheus Holdings, Inc. compare | $269.9M |
| AMRX AMNEAL PHARMACEUTICALS, INC. compare | $209.5M |
| LQDA Liquidia Corporation compare | $138.6M |
| KNSA Kiniksa Pharmaceuticals International, plc compare | $109.6M |
| ALKS Alkermes plc compare | −$351.0K |
| HIMS Hims & Hers Health, Inc. compare | −$142.0M |
| AMLX Amylyx Pharmaceuticals, Inc. compare | −$152.1M |
What Net income is
Net Income tells an investor how much profit a company kept in a period after every cost, interest charge and tax.
Reported line item
More on SUPN
- Revenue
- EPS (diluted)
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- EV/FCF
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- Revenue growth
- Piotroski F-score
- Altman Z-score
- Beneish M-score
- The full statement